Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...

Three months ago, in its third-quarter report, Madrigal pointed out that it achieved a key goal early by gaining 80% coverage ...

Madrigal Pharmaceuticals Inc (MDGL) reports robust financial performance with significant milestones in Rezdiffra's launch ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

H.C. Wainwright raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $405 from $400 and keeps a Buy rating on the shares ...

BofA raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $239 from $154 and keeps an Underperform rating on ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Rising rates of metabolic dysfunction–associated steatohepatitis indicate a need for public health interventions.